Novel molecular targets for urothelial carcinoma
暂无分享,去创建一个
[1] Laura B. Machado,et al. A phase II study of cabozantinib in patients (pts) with relapsed/refractory metastatic urothelial carcinoma (mUC) , 2016 .
[2] F. Real,et al. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non‐muscle invasive tumors , 2015, Molecular carcinogenesis.
[3] Benjamin J. Ainscough,et al. Abstract LB-327: Loss of PTEN leads to clinical resistance to the PI3Kα inhibitor BYL719 and provides evidence of convergent evolution under selective therapeutic pressure , 2014 .
[4] L. Sequist,et al. Abstract CT326: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors , 2014 .
[5] J. Tabernero,et al. Abstract CT325: First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors , 2014 .
[6] P. Stephens,et al. Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] S. Gabriel,et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. , 2014, Cancer discovery.
[8] P. Hegde,et al. Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). , 2014 .
[9] Y. Allory,et al. PI3K/AKT pathway activation in bladder carcinogenesis , 2014, International journal of cancer.
[10] M. Fiorentino,et al. Learning from errors: response to gefitinib in kidney urothelial carcinoma with EGFR mutations. , 2014, The oncologist.
[11] W. Schulz,et al. Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells , 2014, Cancer biology & therapy.
[12] S. Gabriel,et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. , 2014, Cancer discovery.
[13] S. Steinberg,et al. A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC). , 2014 .
[14] Kai Wang,et al. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy , 2014, Modern Pathology.
[15] Steven J. M. Jones,et al. Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.
[16] S. Gabriel,et al. Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.
[17] D. Lamm,et al. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer. , 2014, Urologic oncology.
[18] Jennifer Couzin-Frankel,et al. Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.
[19] Kai Wang,et al. A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma , 2013, Clinical Cancer Research.
[20] P. Albers,et al. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. , 2013, Urologic oncology.
[21] C. Sander,et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] A. Ashworth,et al. Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. , 2013, Cancer discovery.
[23] J. Machiels,et al. PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation , 2013, British Journal of Cancer.
[24] I. Ostrovnaya,et al. Phase II study of everolimus in metastatic urothelial cancer , 2013, BJU international.
[25] Steven J. M. Jones,et al. Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.
[26] N. Gray,et al. TSC1 involvement in bladder cancer: diverse effects and therapeutic implications , 2013, The Journal of pathology.
[27] Steven J. M. Jones,et al. Integrated genomic characterization of endometrial carcinoma , 2013, Nature.
[28] G. Iyer,et al. Fibroblast growth factor receptor-3 in urothelial tumorigenesis. , 2013, Urologic oncology.
[29] D. Bajorin,et al. Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] M. Knowles,et al. PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs , 2013, Oncogene.
[31] M. Knowles,et al. Oncogenic FGFR3 gene fusions in bladder cancer , 2012, Human molecular genetics.
[32] C. Sander,et al. Genome Sequencing Identifies a Basis for Everolimus Sensitivity , 2012, Science.
[33] J. Machiels,et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] E. Plimack,et al. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] M. Knowles,et al. A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges , 2012, Advances in urology.
[36] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[37] A. Ferrari,et al. mTOR signaling pathway and mTOR inhibitors in cancer therapy. , 2012, Hematology/oncology clinics of North America.
[38] Levi A Garraway,et al. Circumventing cancer drug resistance in the era of personalized medicine. , 2012, Cancer discovery.
[39] J. Catto,et al. Molecular mechanisms of cisplatin resistance in bladder cancer , 2012, Expert review of anticancer therapy.
[40] T. H. van der Kwast,et al. The FGFR3 mutation is related to favorable pT1 bladder cancer. , 2009, The Journal of urology.
[41] Huanming Yang,et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder , 2011, Nature Genetics.
[42] M. Day,et al. Urothelial carcinomas: a focus on human epidermal receptors signaling. , 2011, American journal of translational research.
[43] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[44] M. Höglund,et al. A Systematic Study of Gene Mutations in Urothelial Carcinoma; Inactivating Mutations in TSC2 and PIK3R1 , 2011, PloS one.
[45] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[46] J. Oh,et al. The histone deacetylase inhibitor trichostatin A synergistically resensitizes a cisplatin resistant human bladder cancer cell line. , 2011, The Journal of urology.
[47] M. Knowles,et al. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo , 2010, British Journal of Cancer.
[48] J. Wolchok,et al. Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial , 2010, Clinical Cancer Research.
[49] C. Tangen,et al. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium , 2010, BJU international.
[50] H Snowden,et al. AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K , 2010, Oncogene.
[51] F. Radvanyi,et al. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[52] A. Surolia,et al. Heat-shock protein 70-2 (HSP70-2) expression in bladder urothelial carcinoma is associated with tumour progression and promotes migration and invasion. , 2010, European journal of cancer.
[53] W. Gregory,et al. Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer , 2009, Clinical Cancer Research.
[54] L. Margaritis,et al. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses. , 2009, International journal of oncology.
[55] D. Bajorin,et al. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[56] C. Cordon-Cardo,et al. Inactivation of p53 and Pten promotes invasive bladder cancer. , 2009, Genes & development.
[57] L. Cantley,et al. PI3K pathway alterations in cancer: variations on a theme , 2008, Oncogene.
[58] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[59] S. Groshen,et al. Phase II study of vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in patients with advanced transitional cell urothelial cancer (TCC) after platinum-based therapy—California Cancer Consortium/University of Pittsburgh NCI/CTEP-sponsored trial , 2008 .
[60] P. Alken,et al. Optimizing chemotherapy for transitional cell carcinoma by application of bcl-2 and bcl-xL antisense oligodeoxynucleotides. , 2007, Urologic oncology.
[61] J. Machiels,et al. Trastuzumab (T) combined with standard chemotherapy in HER+ metastatic bladder cancer (BC) patients: Interim safety results of a prospective randomized phase II study , 2007 .
[62] David C. Smith,et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] M. Gleave,et al. Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells , 2007, Molecular Cancer Therapeutics.
[64] T. Mak,et al. Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients. , 2006, Cancer research.
[65] N. Malats,et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. , 2006, Cancer research.
[66] Kwang Dong Kim,et al. Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. , 2006, Cancer letters.
[67] N. Normanno,et al. Epidermal growth factor receptor (EGFR) signaling in cancer. , 2006, Gene.
[68] L. Schwartz,et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] L. Cantley,et al. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. , 2003, Cancer cell.
[70] K. Grigor,et al. HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder , 2003, British Journal of Cancer.
[71] L. Schwartz,et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[72] A. Feller,et al. HER2 overexpression in muscle‐invasive urothelial carcinoma of the bladder: Prognostic implications , 2002, International journal of cancer.
[73] Y. Maehara,et al. Increased expression of multidrug resistance‐associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin , 2002, International journal of cancer.
[74] C. Abbou,et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. , 2001, The American journal of pathology.
[75] Jerry L. Workman,et al. ATP-Dependent Chromatin-Remodeling Complexes , 2000, Molecular and Cellular Biology.
[76] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[77] H. Miyake,et al. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer , 1998, Oncogene.
[78] K. Kohno,et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. , 1996, Cancer research.
[79] A. Hall,et al. Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways. , 1996, European journal of cancer.
[80] D. Neal,et al. Alterations in expression of the multidrug resistance-associated protein (MRP) gene in high-grade transitional cell carcinoma of the bladder. , 1996, British Journal of Cancer.
[81] 谷口 堅,et al. ヒトCanalicular Multispecific Organic Anion Transporter(cMOAT)遺伝子は薬剤蓄積の減少したシスプラチン耐性ヒトがん細胞株で過剰発現している , 1996 .
[82] S. Lippard,et al. Cisplatin and DNA repair in cancer chemotherapy. , 1995, Trends in biochemical sciences.
[83] Wun-Jae Kim,et al. Multidrug Resistance‐associated Protein‐mediated Multidrug Resistance Modulated by Cyclosporin A in a Human Bladder Cancer Cell Line , 1995, Japanese journal of cancer research : Gann.
[84] J. Yodoi,et al. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. , 1995, Cancer research.
[85] M. Becich,et al. Absence of immunohistochemical metallothionein staining in bladder tumor specimens predicts response to neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy. , 1994, The Journal of urology.
[86] Shivendra V. Singh,et al. Characterization of a human bladder cancer cell line selected for resistance to mitomycin C , 1994, International journal of cancer.
[87] M. Cohen,et al. DNA ploidy and P-glycoprotein expression as predictive factors of response to neoadjuvant chemotherapy for invasive bladder cancer. , 1994, Urology.
[88] T. Tsuruo,et al. Establishment and characterization of doxorubicin-resistant human bladder cancer cell line, KK47/ADM. , 1992, The Journal of urology.
[89] R. Knuechel,et al. Development and characterization of cisplatin-resistant human testicular and bladder tumour cell lines. , 1990, European journal of cancer.